CHANGSHU, China, and GOTHENBURG, Sweden—Mölnlycke Health Care, a global provider in medical technology, headquartered in Gothenburg, Sweden, announced the commencement of its new wound care manufacturing site in Changshu, China. The company said this investment marks a milestone in Mölnlycke’s growth and the beginning of localized manufacturing in one of the world’s "fastest-growing MedTech markets."
“Our site in Changshu marks another step forward in Mölnlycke’s ambition to manufacture products closer to where they are sold. It reflects our glocal approach, combining global standards with local relevance and reinforces our commitment to sustainable growth, supply chain resilience and faster delivery of life-changing wound care solutions to caregivers and patients in China,” said Zlatko Rihter, CEO of Mölnlycke.
The manufacturing site, spanning 10,000 square meters, will be set up in accordance with Mölnlycke’s global standards and is expected to initiate production of Mölnlycke wound care products at the end of 2026 or in early 2027.
“This investment brings us closer to our customers in China and reinforces our mission to free patients and caregivers from the burden of wounds, with locally produced, high-quality solutions,” adds Jakob Sonnenberg, vice president Greater China & India Wound Care at Mölnlycke.